Patent law in India has evolved significantly over the past decades, shaped by legislative reforms, international obligations, and crucial judicial pronouncements. Landmark cases have played a pivotal role in defining how the Patents Act, 1970 is interpreted, the limits of patentability, the standards for novelty and inventive step, the concept of evergreening, the scope of pharmaceutical patents, enforcement mechanisms, infringement principles, and the balance between public interest and private exclusive rights. These judicial decisions have clarified ambiguities in the law and have provided guidance for inventors, start-ups, corporations, policymakers, and legal practitioners.
This article presents a comprehensive analysis of the most important patent cases in India, explaining their background, legal issues, reasoning, and impact on the development of Indian patent jurisprudence.
I. Novartis AG v. Union of India (2013)
The Novartis case is perhaps the most internationally recognised Indian patent judgment. It shaped the interpretation of pharmaceutical patentability, especially with respect to incremental inventions.
Background
Novartis applied for a patent in India for the beta-crystalline form of Imatinib Mesylate, used in the cancer drug Glivec. The application was rejected under Section 3(d) of the Patents Act, which prohibits patents on new forms of known substances unless they demonstrate enhanced efficacy.
Legal Issue
Whether the beta-crystalline form constituted an invention under Section 2(1)(j) and whether it satisfied the enhanced efficacy requirement under Section 3(d).
Court’s Reasoning
The Supreme Court held that:
- The invention did not demonstrate significant improvement in therapeutic efficacy.
- Section 3(d) was enacted to prevent evergreening, whereby pharmaceutical companies obtain patents on trivial modifications.
- Enhanced solubility or stability did not amount to enhanced therapeutic efficacy.
Impact
This ruling established India’s strong stance against evergreening, making it clear that only genuine pharmaceutical innovations qualify for patents. It also reinforced Section 3(d) as a safeguard ensuring access to affordable medicines.
II. Bayer Corporation v. Union of India (2014)
This case addressed compulsory licensing and clarified how public interest interacts with patent rights.
Background
Bayer held a patent over Sorafenib Tosylate, a drug used for renal cancer treatment. Natco Pharma applied for a compulsory licence under Section 84 on grounds that the drug was unaffordable and insufficiently available.
Legal Issue
Whether the conditions under Section 84 were satisfied for issuance of a compulsory licence.
Court’s Reasoning
The Intellectual Property Appellate Board and later the Bombay High Court upheld the compulsory licence on the following grounds:
- The patented drug was not reasonably priced and was beyond the reach of affected patients.
- Bayer had not sufficiently worked the patent in India.
- Public interest justified granting a compulsory licence.
Impact
This case established India’s commitment to balancing patent rights with public health. It remains a landmark precedent on when compulsory licences may be granted.
III. F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2008, 2015)
This litigation is one of India’s first major pharmaceutical patent infringement cases and laid down foundational principles for infringement and claim construction.
Background
Roche sued Cipla for infringing its patent relating to the cancer drug Erlotinib (Tarceva). Cipla argued invalidity of the patent and invoked public interest.
Legal Issues
- What standard should be applied for claim construction?
- Can courts refuse injunctions in pharmaceutical cases based on public interest?
Court’s Reasoning
The Delhi High Court held:
- Claims determine the scope of protection; description merely aids interpretation.
- Public interest can be a factor when deciding interim injunctions in life-saving drug cases.
- Cipla was allowed to manufacture owing to public interest, but the patent was upheld as valid.
Impact
This case clarified the principle that claims, not abstracts or titles, define patent boundaries. It also recognised public interest as a factor in balancing exclusive rights.
IV. Biswanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979)
A foundational judgment on novelty, inventive step, and claim construction.
Background
The dispute concerned a patent for a kitchen utensil. The defendant challenged its novelty and inventive step.
Legal Issue
Whether the invention was truly novel and involved an inventive step.
Court’s Reasoning
The Supreme Court held:
- A patent must involve a technical advance over prior art.
- The claims must be read in light of the specification but ultimately determine the scope.
- Mere workshop improvements or obvious modifications are not patentable.
Impact
This case remains a leading authority on novelty and inventive step in India, influencing subsequent judgments interpreting Section 2(1)(ja).
V. Enercon (India) Ltd. v. Aloys Wobben (2014)
This case defines rules for patent ownership disputes and strategies involving multiple filings.
Background
The dispute involved numerous patents related to wind turbine technology filed by the German inventor Aloys Wobben and Enercon India.
Legal Issue
Whether both revocation and infringement can proceed simultaneously and who had valid ownership.
Court’s Reasoning
The Supreme Court held:
- A patentee cannot maintain both revocation and infringement proceedings simultaneously.
- Ownership must be clearly established before suing.
Impact
This case clarified procedural law relating to revocation under Section 64 and infringement suits under Section 104.
VI. Telefonaktiebolaget LM Ericsson v. Intex Technologies (2016)
A landmark case concerning Standard Essential Patents (SEPs) and FRAND licensing in India.
Background
Ericsson, holding SEPs related to mobile technology, sued Intex for patent infringement. Intex argued that Ericsson was demanding discriminatory royalty rates.
Legal Issues
- How should courts handle disputes involving SEPs?
- What constitutes fair, reasonable, and non-discriminatory (FRAND) licensing?
Court’s Reasoning
The Delhi High Court held:
- Holders of SEPs must offer FRAND licences.
- Implementers cannot avoid infringement simply by alleging unfair licensing.
- Injunctions may be granted even for SEPs if negotiations fail.
Impact
This case brought clarity to India’s approach to SEPs, an area critical to telecom and technology industries.
VII. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2018)
A prominent case about the patentability of genetically modified traits in seeds.
Background
Monsanto owned patents over Bt cotton technology. Nuziveedu argued that plant varieties cannot be patented under Section 3(j).
Legal Issue
Whether plant genetic traits inserted into seeds are patentable.
Court’s Reasoning
The Delhi High Court initially held that Monsanto’s patent was valid. The Division Bench later held that the invention did not qualify as patentable subject matter under Section 3(j) since plant varieties are excluded.
The Supreme Court set aside the Division Bench judgment and ordered fresh hearing.
Impact
The case clarified the fine boundaries of patentability in biotechnology and reinforced the importance of Section 3 exclusions.
VIII. Merck Sharp & Dohme v. Glenmark (2015)
A key judgment reinforcing strong patent enforcement in India.
Background
Merck sued Glenmark for infringing its Sitagliptin patent used for diabetes treatment.
Legal Issue
Whether Glenmark’s product Gliptin infringed Merck’s patent.
Court’s Reasoning
The Delhi High Court held:
- Merck’s patent was valid and enforceable.
- Glenmark’s product was identical in function and composition.
- An interim injunction was warranted.
Impact
This case strengthened India’s jurisprudence on pharmaceutical patent enforcement and clarified infringement principles under Section 48.
IX. Philips v. Amaze Store (2019)
One of India’s largest patent infringement damages awards.
Background
Philips held patents relating to DVD technology. The defendants were selling infringing DVD players.
Legal Issue
Whether the defendants infringed and what damages should be awarded.
Court’s Reasoning
The Delhi High Court held:
- The defendants infringed the patents.
- Damages must be deterrent in cases of blatant infringement.
- Philips was awarded substantial damages.
Impact
This case marked a shift toward stronger enforcement and higher damages in India.
X. Bajaj Auto Ltd. v. TVS Motor Company Ltd. (2009)
A landmark case involving mechanical and automotive patent claims.
Background
Bajaj claimed that TVS infringed its patent relating to combustion chamber technology.
Legal Issue
Whether TVS’s motorcycle infringed Bajaj’s patent and whether the injunction was justified.
Court’s Reasoning
The Supreme Court emphasised:
- The need for technical comparison of claims.
- That interim injunctions should be granted cautiously.
Impact
This decision shaped how courts analyse technical patents, establishing careful judicial scrutiny.
XI. Chemtura Corporation v. Union of India (2009)
A major case concerning patent working and interim injunctions.
Background
Chemtura accused Indian companies of infringing its patents relating to pesticides.
Legal Issue
Whether an interim injunction was appropriate when the patent was not sufficiently worked in India.
Court’s Reasoning
The Delhi High Court held:
- Patents must be “worked” in India under Section 83 principles.
- Non-working affects grant of temporary injunctions.
Impact
The decision reinforced India’s emphasis on domestic technological access.
XII. Ferid Allani v. Union of India (2019)
A crucial case concerning software and computer-related inventions.
Background
Ferid Allani filed a patent application for an internet-based kiosk system. It was rejected under Section 3(k), which excludes algorithms and computer programs per se.
Legal Issue
Whether software-related inventions demonstrating technical effect are patentable.
Court’s Reasoning
The Delhi High Court held:
- If an invention produces a technical effect or solves a technical problem, it is patentable.
- Section 3(k) cannot be applied mechanically.
Impact
This case opened the door for AI and software-based inventions to be patented if they demonstrate technical advancement.
Conclusion
Landmark patent cases in India have profoundly shaped the country’s innovation ecosystem. Through these judicial interpretations, Indian courts have clarified the scope of patentable subject matter, the standards for pharmaceutical patentability, the boundaries of biotech patents, the rules for compulsory licences, the principles governing infringement, the limits of software patents, and the enforcement of rights in domestic and international contexts.
These decisions collectively reinforce that Indian patent law is not merely a mechanical extension of international norms but a carefully balanced framework that protects genuine innovation while safeguarding public interest. The judiciary has consistently upheld strict patentability standards, rejected evergreening, strengthened enforcement of valid patents, encouraged fair licensing of essential technologies, and promoted accessibility to medicines and agricultural technologies.
As India continues its transformation into a global innovation hub, the evolving jurisprudence arising from these landmark cases will remain critical in influencing the direction of patent law, guiding innovators, and maintaining equilibrium between exclusive rights and societal welfare
Leave a Reply